159 related articles for article (PubMed ID: 30543359)
1. Cyclin-Dependent Kinase Inhibitor-Associated Thromboembolism.
Olson SR; DeLoughery TG; Shatzel JJ
JAMA Oncol; 2019 Feb; 5(2):141-142. PubMed ID: 30543359
[No Abstract] [Full Text] [Related]
2. The evolving role of cyclin-dependent kinase inhibitors in cancer management.
Shapiro GI
Clin Adv Hematol Oncol; 2017 Mar; 15(3):174-177. PubMed ID: 28398270
[No Abstract] [Full Text] [Related]
3. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
Bruyère C; Meijer L
Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
6. Recent advances on CDK inhibitors: An insight by means of in silico methods.
Tutone M; Almerico AM
Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
[TBL] [Abstract][Full Text] [Related]
7. Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Giannone G; Tuninetti V; Ghisoni E; Genta S; Scotto G; Mittica G; Valabrega G
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31083638
[TBL] [Abstract][Full Text] [Related]
8. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
9. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
10. Re: preclinical and clinical development of cyclin-dependent kinase modulators.
Darzynkiewicz Z
J Natl Cancer Inst; 2000 Jul; 92(14):1184-5. PubMed ID: 10904096
[No Abstract] [Full Text] [Related]
11. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Senderowicz AM
Prog Drug Res; 2005; 63():183-206. PubMed ID: 16265881
[TBL] [Abstract][Full Text] [Related]
13. Atrial Fibrillation: Considerations for the Use of BTK Inhibitors.
Valla K
Oncology (Williston Park); 2018 Nov; 32(11):574-5. PubMed ID: 30474106
[No Abstract] [Full Text] [Related]
14. Promises and drawbacks of targeting cell cycle kinases in cancer.
Pentimalli F; Giordano A
Discov Med; 2009 Dec; 8(43):177-80. PubMed ID: 20040266
[TBL] [Abstract][Full Text] [Related]
15. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
16. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
17. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
Pitts TM; Davis SL; Eckhardt SG; Bradshaw-Pierce EL
Pharmacol Ther; 2014 May; 142(2):258-69. PubMed ID: 24362082
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.
Zhu G; Conner SE; Zhou X; Chan HK; Shih C; Engler TA; Al-Awar RS; Brooks HB; Watkins SA; Spencer CD; Schultz RM; Dempsey JA; Considine EL; Patel BR; Ogg CA; Vasudevan V; Lytle ML
Bioorg Med Chem Lett; 2004 Jun; 14(12):3057-61. PubMed ID: 15149644
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres.
Jorda R; Paruch K; Krystof V
Curr Pharm Des; 2012; 18(20):2974-80. PubMed ID: 22571665
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitors for treating cancer.
Toogood PL
Med Res Rev; 2001 Nov; 21(6):487-98. PubMed ID: 11607930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
